The Discounted Cash Flow (DCF) valuation of Protalix Biotherapeutics Inc (PLX) is 9.30 USD. With the latest stock price at 1.54 USD, the upside of Protalix Biotherapeutics Inc based on DCF is 504.2%.
Based on the latest price of 1.54 USD and our DCF valuation, Protalix Biotherapeutics Inc (PLX) is a buy. buying PLX stocks now will result in a potential gain of 504.2%.
| Range | Selected | |
| WACC / Discount Rate | 5.2% - 7.5% | 6.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 5.02 - 87.13 | 9.30 |
| Upside | 226.2% - 5558.0% | 504.2% |